Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.
Ledgerwood JE, Bellamy AR, Belshe R, Bernstein DI, Edupuganti S, Patel SM, Renehan P, Zajdowicz T, Schwartz R, Koup R, Bailer RT, Yamshchikov GV, Enama ME, Sarwar U, Larkin B, Graham BS; VRC 701 study team. Ledgerwood JE, et al. Among authors: edupuganti s. PLoS One. 2015 May 7;10(5):e0125914. doi: 10.1371/journal.pone.0125914. eCollection 2015. PLoS One. 2015. PMID: 25950433 Free PMC article. Clinical Trial.
Natural infection by Zika virus but not DNA vaccination consistently elicits antibodies that compete with two potently neutralising monoclonal antibodies targeting distinct epitopes.
Smith TC, Espinoza DO, Zhu Y, Cardona-Ospina JA, Bowman NM, Becker-Dreps S, Rouphael N, Rodriguez-Morales AJ, Bucardo F, Edupuganti S, Premkumar L, Mulligan MJ, de Silva AM, Collins MH. Smith TC, et al. Among authors: edupuganti s. EBioMedicine. 2023 Dec;98:104875. doi: 10.1016/j.ebiom.2023.104875. Epub 2023 Nov 18. EBioMedicine. 2023. PMID: 37983984 Free PMC article.
Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.
Belshe RB, Frey SE, Graham I, Mulligan MJ, Edupuganti S, Jackson LA, Wald A, Poland G, Jacobson R, Keyserling HL, Spearman P, Hill H, Wolff M; National Institute of Allergy and Infectious Diseases-Funded Vaccine and Treatment Evaluation Units. Belshe RB, et al. Among authors: edupuganti s. J Infect Dis. 2011 Mar 1;203(5):666-73. doi: 10.1093/infdis/jiq093. Epub 2011 Jan 31. J Infect Dis. 2011. PMID: 21282194 Free PMC article. Clinical Trial.
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.
Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed R. Li GM, et al. Among authors: edupuganti s. Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9047-52. doi: 10.1073/pnas.1118979109. Epub 2012 May 21. Proc Natl Acad Sci U S A. 2012. PMID: 22615367 Free PMC article.
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team. Hammer SM, et al. N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7. N Engl J Med. 2013. PMID: 24099601 Free PMC article. Clinical Trial.
Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, Ince D, Noah DL, Hill H, Bellamy AR; DMID 13-0032 H7N9 Vaccine Study Group. Mulligan MJ, et al. Among authors: edupuganti s. JAMA. 2014 Oct 8;312(14):1409-19. doi: 10.1001/jama.2014.12854. JAMA. 2014. PMID: 25291577 Clinical Trial.
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB, Frey SE, Graham IL, Anderson EL, Jackson LA, Spearman P, Edupuganti S, Mulligan MJ, Rouphael N, Winokur P, Dolor RJ, Woods CW, Walter EB, Chen WH, Turley C, Edwards KM, Creech CB, Hill H, Bellamy AR; National Institute of Allergy and Infectious Diseases–Funded Vaccine and Treatment Evaluation Units. Belshe RB, et al. Among authors: edupuganti s. JAMA. 2014 Oct 8;312(14):1420-8. doi: 10.1001/jama.2014.12609. JAMA. 2014. PMID: 25291578 Clinical Trial.
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, Wolff M, Belshe RB. Frey SE, et al. Among authors: edupuganti s. Vaccine. 2015 Jan 1;33(1):163-73. doi: 10.1016/j.vaccine.2014.10.083. Epub 2014 Nov 11. Vaccine. 2015. PMID: 25444805 Free PMC article. Clinical Trial.
Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.
Keitel WA, Jackson LA, Edupuganti S, Winokur PL, Mulligan MJ, Thornburg NJ, Patel SM, Rouphael NG, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR; VTEU H3N2v Vaccine Study Work Group. Keitel WA, et al. Among authors: edupuganti s. J Infect Dis. 2015 Aug 15;212(4):552-61. doi: 10.1093/infdis/jiv056. Epub 2015 Feb 3. J Infect Dis. 2015. PMID: 25649171 Free PMC article.
148 results